1
|
Jelovac D and Armstrong DK: Recent
progress in the diagnosis and treatment of ovarian cancer. CA
Cancer J Clin. 61:183–203. 2011. View Article : Google Scholar : PubMed/NCBI
|
2
|
Katsumata N: Dose-dense approaches to
ovarian cancer treatment. Curr Treat Options Oncol. 16:212015.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Yamaguchi H and Hung MC: Regulation and
role of EZH2 in cancer. Cancer Res Treat. 46:209–222. 2014.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Han T, Jiao F, Hu H, Yuan C, Wang L, Jin
ZL, Song WF and Wang LW: EZH2 promotes cell migration and invasion
but not alters cell proliferation by suppressing E-cadherin, partly
through association with MALAT-1 in pancreatic cancer. Oncotarget.
7:11194–11207. 2016.PubMed/NCBI
|
5
|
Guo S, Li X, Rohr J, Wang Y, Ma S, Chen P
and Wang Z: EZH2 overexpression in different immunophenotypes of
breast carcinoma and association with clinicopathologic features.
Diagn Pathol. 11:412016. View Article : Google Scholar : PubMed/NCBI
|
6
|
Zhang Y, Lin C, Liao G, Liu S, Ding J,
Tang F, Wang Z, Liang X, Li B, Wei Y, et al: MicroRNA-506
suppresses tumor proliferation and metastasis in colon cancer by
directly targeting the oncogene EZH2. Oncotarget. 6:32586–32601.
2015.PubMed/NCBI
|
7
|
Guo J, Cai J, Yu L, Tang H, Chen C and
Wang Z: EZH2 regulates expression of p57 and contributes to
progression of ovarian cancer in vitro and in vivo. Cancer Sci.
102:530–539. 2011. View Article : Google Scholar : PubMed/NCBI
|
8
|
Rayess H, Wang MB and Srivatsan ES:
Cellular senescence and tumor suppressor gene p16. Int J Cancer.
130:1715–1725. 2012. View Article : Google Scholar : PubMed/NCBI
|
9
|
Zhao R, Choi BY, Lee MH, Bode AM and Dong
Z: Implications of genetic and epigenetic alterations of CDKN2A
(p16INK4a) in cancer. EBioMedicine. 8:30–39. 2016. View Article : Google Scholar : PubMed/NCBI
|
10
|
Cui C, Gan Y, Gu L, Wilson J, Liu Z, Zhang
B and Deng D: P16-specific DNA methylation by engineered zinc
finger methyltransferase inactivates gene transcription and
promotes cancer metastasis. Genome Biol. 16:2522015. View Article : Google Scholar : PubMed/NCBI
|
11
|
Lee MH, Choi BY, Cho YY, Lee SY, Huang Z,
Kundu JK, Kim MO, Kim DJ, Bode AM, Surh YJ and Dong Z: Tumor
suppressor p16(INK4a) inhibits cancer cell growth by downregulating
eEF1A2 through a direct interaction. J Cell Sci. 126:1744–1752.
2013. View Article : Google Scholar : PubMed/NCBI
|
12
|
Kong R, Zhang EB, Yin DD, You LH, Xu TP,
Chen WM, Xia R, Wan L, Sun M, Wang ZX, et al: Long noncoding RNA
PVT1 indicates a poor prognosis of gastric cancer and promotes cell
proliferation through epigenetically regulating p15 and p16. Mol
Cancer. 14:822015. View Article : Google Scholar : PubMed/NCBI
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Liu XS, Wu H, Ji X, Stelzer Y, Wu X,
Czauderna S, Shu J, Dadon D, Young RA and Jaenisch R: Editing DNA
methylation in the mammalian genome. Cell. 167:233–247.e17. 2016.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Brunmeir R, Lagger S, Simboeck E, Sawicka
A, Egger G, Hagelkruys A, Zhang Y, Matthias P, Miller WJ and Seiser
C: Epigenetic regulation of a murine retrotransposon by a dual
histone modification mark. PLoS Genet. 6:e10009272010. View Article : Google Scholar : PubMed/NCBI
|
16
|
Zhou CY, Johnson SL, Gamarra NI and
Narlikar GJ: Mechanisms of ATP-dependent chromatin remodeling
motors. Annu Rev Biophys. 45:153–181. 2016. View Article : Google Scholar : PubMed/NCBI
|
17
|
Engreitz JM, Ollikainen N and Guttman M:
Long non-coding RNAs: Spatial amplifiers that control nuclear
structure and gene expression. Nat Rev Mol Cell Biol. 17:756–770.
2016. View Article : Google Scholar : PubMed/NCBI
|
18
|
Chinaranagari S, Sharma P and Chaudhary J:
EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4
in prostate cancer. Oncotarget. 5:7172–7182. 2014. View Article : Google Scholar : PubMed/NCBI
|
19
|
Luo H, Jiang Y, Ma S, Chang H, Yi C, Cao
H, Gao Y, Guo H, Hou J, Yan J, et al: EZH2 promotes invasion and
metastasis of laryngeal squamous cells carcinoma via
epithelial-mesenchymal transition through H3K27me3. Biochem Biophys
Res Commun. 479:253–259. 2016. View Article : Google Scholar : PubMed/NCBI
|
20
|
Benard A, Goossens-Beumer IJ, van Hoesel
AQ, Horati H, Putter H, Zeestraten EC, van de Velde CJ and Kuppen
P: Prognostic value of polycomb proteins EZH2, BMI1 and SUZ12 and
histone modification H3K27me3 in colorectal cancer. PLoS One.
9:e1082652014. View Article : Google Scholar : PubMed/NCBI
|
21
|
Zhou W, Wang J, Man WY, Zhang QW and Xu
WG: siRNA silencing EZH2 reverses cisplatin-resistance of human
non-small cell lung and gastric cancer cells. Asian Pac J Cancer
Prev. 16:2425–2430. 2015. View Article : Google Scholar : PubMed/NCBI
|
22
|
Zhang Q, Padi SK, Tindall DJ and Guo B:
Polycomb protein EZH2 suppresses apoptosis by silencing the
proapoptotic miR-31. Cell Death Dis. 5:e14862014. View Article : Google Scholar : PubMed/NCBI
|
23
|
Al-Khalaf HH and Aboussekhra A: p16(INK4A)
positively regulates p21(WAF1) expression by suppressing
AUF1-dependent mRNA decay. PLoS One. 8:e701332013. View Article : Google Scholar : PubMed/NCBI
|
24
|
Chang Z, Ju H, Ling J, Zhuang Z, Li Z,
Wang H, Fleming JB, Freeman JW, Yu D, Huang P and Chiao PJ:
Cooperativity of oncogenic K-Ras and downregulated p16/INK4A in
human pancreatic tumorigenesis. PLoS One. 9:e1014522014. View Article : Google Scholar : PubMed/NCBI
|
25
|
McLaughlin-Drubin ME, Park D and Munger K:
Tumor suppressor p16INK4A is necessary for survival of cervical
carcinoma cell lines. Proc Natl Acad Sci USA. 110:pp. 16175–16180.
2013; View Article : Google Scholar : PubMed/NCBI
|
26
|
Qi W, Chan H, Teng L, Li L, Chuai S, Zhang
R, Zeng J, Li M, Fan H, Lin Y, et al: Selective inhibition of Ezh2
by a small molecule inhibitor blocks tumor cells proliferation.
Proc Natl Acad Sci USA. 109:pp. 21360–21365. 2012; View Article : Google Scholar : PubMed/NCBI
|